11.19.19
GenScript Biologics, a biopharmaceutical CDMO, has entered into an agreement with ABL Bio Inc., a South Korean biotech company dedicated to therapeutics for immuno-oncology and neurodegenerative diseases, for two bispecific antibody programs.
GenScript will grant a sublicense to ABL Bio to use sdAb (single-domain antibody), mAb (monoclonal antibody) targeting tumor antigens, and its Single-Domain Antibody fused to Monoclonal Ab (SMAB) Platform to develop several bispecific antibody molecules. will appoint GenScript will serve as ABL Bio’s exclusive supplier of CDMO services for IND-enabling studies and clinical material manufacturing to help accelerate the development of the bispecific antibody under the licensing agreement. GenScript will provide support and services for the programs. GenScript will receive an upfront and milestone payments, and royalties. The companies will leverage their resources to further expand ABL Bio's bispecific antibody development pipelines.
"We are glad to cooperate with GenScript. GenScript is growing fast in recent years and has facilitated several companies to make achievements in antibody drug research," said Dr. Sang Hoon Lee, chief executive officer of ABL Bio, "We expect the outstanding druggability and streamlined production processes of GenScript's SMAB platform to accelerate the development of novel immunotherapy and the launch of new drugs. This partnership will further expand our bispecific antibody development pipelines, and help us ascend to a leader in therapeutics for immuno-oncology and neurodegenerative diseases."
"We are excited about this collaboration with ABL Bio, an experienced company in the bispecific antibody field, which manifests that GenScript's biologics R&D services have been increasingly recognized by global well-known enterprises," Dr. Brian Min, chief executive officer of GenScript Biologics, said, "GenScript has extensive experience and powerful teams in biologics R&D. We would like to cooperate with more well-positioned enterprises like ABL Bio, utilize our own powerful R&D advantages, and accelerate the development of novel antibody drugs."
GenScript will grant a sublicense to ABL Bio to use sdAb (single-domain antibody), mAb (monoclonal antibody) targeting tumor antigens, and its Single-Domain Antibody fused to Monoclonal Ab (SMAB) Platform to develop several bispecific antibody molecules. will appoint GenScript will serve as ABL Bio’s exclusive supplier of CDMO services for IND-enabling studies and clinical material manufacturing to help accelerate the development of the bispecific antibody under the licensing agreement. GenScript will provide support and services for the programs. GenScript will receive an upfront and milestone payments, and royalties. The companies will leverage their resources to further expand ABL Bio's bispecific antibody development pipelines.
"We are glad to cooperate with GenScript. GenScript is growing fast in recent years and has facilitated several companies to make achievements in antibody drug research," said Dr. Sang Hoon Lee, chief executive officer of ABL Bio, "We expect the outstanding druggability and streamlined production processes of GenScript's SMAB platform to accelerate the development of novel immunotherapy and the launch of new drugs. This partnership will further expand our bispecific antibody development pipelines, and help us ascend to a leader in therapeutics for immuno-oncology and neurodegenerative diseases."
"We are excited about this collaboration with ABL Bio, an experienced company in the bispecific antibody field, which manifests that GenScript's biologics R&D services have been increasingly recognized by global well-known enterprises," Dr. Brian Min, chief executive officer of GenScript Biologics, said, "GenScript has extensive experience and powerful teams in biologics R&D. We would like to cooperate with more well-positioned enterprises like ABL Bio, utilize our own powerful R&D advantages, and accelerate the development of novel antibody drugs."
